2 The technology

2 The technology

Marketing authorisation indication

Avelumab (Bavencio, Merck) is indicated as monotherapy for 'the treatment of adult patients with metastatic Merkel cell carcinoma'.

Dosage in the marketing authorisation

10 mg/kg every 2 weeks by intravenous infusion over 60 minutes.

Avelumab should be continued until there is disease progression or unacceptable toxicity. Patients could continue treatment if they have radiological disease progression that is not associated with significant clinical deterioration (defined as no new or worsening symptoms, no change in performance status for more than 2 weeks and no need for salvage therapy).


£768 per 200‑mg vial (excluding VAT; Monthly Index of Medical Specialities [MIMS] online [accessed January 2018]). The average cost of treatment per patient is £65,086 based on the list price. Costs may vary in different settings because of negotiated procurement discounts.

In relation to recommendation 1.2, as part of the managed access agreement, the company has a commercial access agreement with NHS England. The financial terms of the agreement are commercial in confidence. The list price applies to recommendation 1.1.

  • National Institute for Health and Care Excellence (NICE)